|Bid||53.05 x 900|
|Ask||54.44 x 800|
|Day's Range||53.44 - 54.32|
|52 Week Range||47.88 - 67.40|
|Beta (5Y Monthly)||0.25|
|PE Ratio (TTM)||24.73|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 08, 2021|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for RDY
HYDERABAD, India & PRINCETON, N.J., September 07, 2022--Dr. Reddy’s Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.
HYDERABAD, India & PRINCETON, N.J., July 29, 2022--Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC.
HYDERABAD, India & PRINCETON, NJ, July 27, 2022--Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market.